NEUROCRINE BIOSCIENCES INC Ttl Fee Amt
NEUROCRINE BIOSCIENCES INC (NBIX) had Ttl Fee Amt of $96.87 thousand as of 2026-07-31, per its S-8 filed 2026-07-31.
Financial Statements › Notes
ffd:TtlFeeAmt · last filed 2026-07-31
- 2026-07-31: Ttl Fee Amt $96.87K.
- 2026-04-17: Ttl Fee Amt $398.03K.
| Period end | Ttl Fee Amt |
|---|---|
| 2026-07-31 | $96.87K S-8 · filed 2026-07-31 |
| 2026-04-17 | $398.03K SC TO-T · filed 2026-04-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |